This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
BriefMEDTECH

Liquid Biopsy Breakthrough: Single Blood Draw Screens for 12 Early-Stage Cancers

Grail's upgraded Galleri test expands cancer screening from 5 to 12 types, with early-stage detection rate rising to 83% and per-test cost dropping to $299.

U.S. liquid biopsy company Grail announced a major upgrade to its Galleri multi-cancer early detection test. The new version can simultaneously screen for 12 cancer types (adding ovarian, pancreatic, esophageal, bladder, liver, thyroid, and gastric cancers), with early-stage (I-II) detection rate rising from 52% to 83%. The per-test cost has dropped from $949 to $299, and it has been incorporated into the UK NHS's national screening pilot program. Analysts expect this to drive cancer early screening from premium checkups to mass adoption.